PMCB · PharmaCyte Biotech, Inc. · Executive Compensation
$0.41
-0.02 (-3.98%)
At close · Oct 7
Return incl. dividend (before tax)
Going-concern doubt
— cleared Sep 14, 2026
The latest filing no longer states the doubt (first flagged Jul 29, 2026).
View the 10-Q filed Sep 14, 2026Market Cap
$4.73M
Shares
10.74M
Volume · Oct 7
97.5K
Avg daily vol (3M)
202.06K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Joshua N. Silverman | Officer and President | $520,257 |
| Carlos A. Trujillo | Officer | $482,017 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Joshua N. Silverman | Officer and Interim President | $787,923 |
| Carlos A. Trujillo | — | $586,462 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Kenneth L. Waggoner | Officer, President and | $441,223 |
| Carlos A. Trujillo | — | $385,259 |
| Joshua N. Silverman | Officer and Interim President | $197,917 |
| Gerald W. Crabtree | Officer | $66,658 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Kenneth L. Waggoner | Officer, President and | $919,151 |
| Carlos A. Trujillo | — | $631,851 |
| Gerald W. Crabtree | Officer | $136,749 |
| Joshua N. Silverman | Officer and Interim President | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Kenneth L. Waggoner | — | $616,505 |
| Carlos A. Trujillo | — | $422,114 |
| Gerald W. Crabtree | — | $137,731 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael M. Abecassis | Director | Appointed | 2026-04-02 |
| Wayne R. Walker | Director | Appointed | 2026-04-02 |
| Robert Weinstein | Director | Appointed | 2026-04-02 |
| Jonathan L. Schechter | Director | Appointed | 2026-04-02 |
| Joshua N. Silverman | Director | Appointed | 2026-04-02 |
| Joshua Silverman | Interim President | Appointed | 2022-11-18 |
| Joshua Silverman | Interim Chief Executive Officer | Appointed | 2022-11-18 |
| Robert Weinstein | member of the Board | Appointed | 2022-11-18 |
| Jack E. Stover | board of directors | Resigned | 2022-11-07 |
| Gerald W. Crabtree | Chief Scientific Officer | Resigned | 2022-10-14 |
| Joshua N. Silverman | interim President | Appointed | 2022-10-07 |
| Joshua N. Silverman | interim Chief Executive Officer | Appointed | 2022-10-07 |
| Joshua N. Silverman | interim Chairman of the Board | Appointed | 2022-10-07 |
| Kenneth L. Waggoner | President and General Counsel | Resigned | 2022-10-07 |
| Kenneth L. Waggoner | director on the Board of Directors | Resigned | 2022-10-07 |
| Kenneth L. Waggoner | Chief Executive Officer | Resigned | 2022-10-07 |
| Carlos Trujillo | Board member | Resigned | 2022-08-16 |
| Thomas Liquard | Board member | Resigned | 2022-08-16 |
| Dr. Raymond C.F. Tong | Board member | Resigned | 2022-08-16 |
| Daniel C. Allen | independent director | Appointed | 2022-08-16 |
| Dr. Gerald W. Crabtree | Board member | Resigned | 2022-08-16 |
| Dr. Matthias Löhr | Board member | Resigned | 2022-08-16 |
| Jack E. Stover | independent director | Appointed | 2022-08-16 |
| Daniel S. Farb | independent director | Appointed | 2022-08-16 |
| Joshua N. Silverman | independent director | Appointed | 2022-08-16 |